At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Cytarabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
In Brief
A Phase 2 clinical trial evaluating Cytarabine and Vosaroxin for Acute Myeloid Leukemia (AML) and 6 related conditions. Completed, enrolled 42 participants across 3 sites.
Detailed Summary
This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartMar 2016
Primary CompletionApr 2019
Study CompletionSep 2024
TodayJul 2026
First PostedJan 18, 2016
Enrollment StartMar 1, 2016
Primary CompletionApr 1, 2019
Study CompletionSep 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.5 years ago
Interventions
Cytarabinedrug
Given IV
Vosaroxindrug
Given IV